Business
Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter
Strong growth in February/March following January seasonality Net revenue approaches US$100M since launch NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil® (remestemcel-L-rknd) net sales were US$30.3 million for the quarter ended March 31, 2026.1 Strong sales in February and March offset holiday seasonality in January. Revenue generated during this first year of
About this update from Mesoblast Limited
[{"type":"image","alt":"Mesoblast Limited","displaySize":"","headline":null,"caption":"Mesoblast Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":289,"height":38,"url":"https://media.zenfs.com/en/globenewswire.com/3a26a2f63129fae6650ef7618b48c2df"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MBpzhI3EX6RmRRSN4a_YSQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTU1/https://media.zenfs.com/en/globenewswire.com/3a26a2f63129fae6650ef7618b48c2df","width":289,"height":38}},"lazy":false},{"type":"text","content":"Strong growth in February/March following January seasonality","length":61,"tagName":"p"},{"type":"text","content":"Net revenue approaches US$100M since launch","length":43,"tagName":"p"},{"type":"text","content":"NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil® (remestemcel-L-rknd) net sales were US$30.3 million for the quarter ended March 31, 2026.1 Strong sales in February and March offset holiday seasonality in January. Revenue generated during this first year of Ryoncil® launch approaches US$100 million.","length":437,"tagName":"p"},{"type":"text","content":"Ryoncil® revenue strengthens Mesoblast's balance sheet and supports label extension and late-stage blockbuster programs. Ryoncil® is the first mesenchymal stromal cell (MSC) product approved by the U.S. Food and Drug Administration (FDA) for any indication and is the only FDA-approved product for children under age 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD).2","length":392,"tagName":"p"},{"type":"text","content":"“Revenue for Ryoncil® continues to be impressive,” said Mesoblast Chief Executive Dr. Silviu Itescu. “We will outline our growth strategy for Ryoncil® as well as our robust late-stage product pipeline at our inaugural R&D event this week.”","length":243,"tagName":"p"},{"type":"text","content":"Mesoblast will host its inaugural R&D Day on Wednesday, April 8, 2026, in New York City. The event will be webcast live from 8:00am to 11:00am EST and will include presentations from Mesoblast’s senior leadership team and from key opinion leaders.","length":251,"tagName":"p"},{"type":"text","content":"The webcast can be accessed via: https://webcast.openbriefing.com/msb-inv-2026/","length":79,"tag...